Compositions and methods for siRNA inhibition of angiogenesis

Details Compositions and methods for siRNA inhibition of angiogenesis Compositions and methods for siRNA inhibition of angiogenesis

2006-06-08

2008-03-18

McGarry, Sean (Department: 1635)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C536S023100, C536S024300, C536S024330, C536S024500

Reexamination Certificate

active

07345027

ABSTRACT:
RNA interference using small interfering RNAs which are specific for the vascular endothelial growth factor (VEGF) gene and the VEGF receptor genes Flt-1 and Flk-1/KDR inhibit expression of these genes. Diseases which involved angiogenesis stimulated by overexpression of VEGF, such as diabetic retinopathy, age related macular degeneration and many types of cancer, can be treated by administering the small interfering RNAs.

REFERENCES:
patent: 6177401 (2001-01-01), Ullrich et al.
patent: 6506559 (2003-01-01), Fire et al.
patent: 2002/0086356 (2002-07-01), Tuschl et al.
patent: 2002/0132788 (2002-09-01), Lewis et al.
patent: 2002/0162126 (2002-10-01), Beach et al.
patent: 2002/0173478 (2002-11-01), Gewirtz
patent: 2003/0138407 (2003-07-01), Lu et al.
patent: 2003/0153519 (2003-08-01), Kay et al.
patent: 2003/0216335 (2003-11-01), Lockridge et al.
patent: 2005/0019927 (2005-01-01), Hildinger et al.
patent: 2006/0292120 (2006-12-01), Tolentino et al.
patent: 2007/0003523 (2007-01-01), Tolentino et al.
patent: 2007/0037760 (2007-02-01), Tolentino et al.
patent: 2007/0037761 (2007-02-01), Tolentino et al.
patent: 2007/0037762 (2007-02-01), Tolentino et al.
patent: 2007/0149471 (2007-06-01), Tolentino et al.
patent: 2359180 (2000-08-01), None
patent: WO 95/04142 (1995-02-01), None
patent: WO 02/096927 (2002-12-01), None
patent: WO 02/096957 (2002-12-01), None
patent: WO 03/070910 (2003-08-01), None
patent: WO 03/087367 (2003-10-01), None
patent: WO 03/087368 (2003-10-01), None
patent: WO 03/099298 (2003-12-01), None
patent: WO 2004/013310 (2004-02-01), None
patent: WO 2006/110813 (2006-10-01), None
Lu et al. (2005). Deliverying siRNA in vivo for functional genomics and novel therapeutics. From RNA Interference Technology (Cambridge, Appasani, ed., pp. 303-317).
Samarsky et al. (2005). RNAi in drug development: Practical considerations. From RNA Interference Technology (Cambridge, Appasani, ed., pp. 384-395).
Downward, J. Science, medicine, and the future. RNA interference. BMJ, 2004 vol. 328:1245-1248.
Nielsen, PE. Systemic delivery. The last hurdle? Gene Therapy, 2005 vol. 12:956-957.
Tolentino et al. Intravitreal injection of vasvular endothelial growth factor small interfering RNA inhibits growth and leakage in a nonhuman primate, laster-induced model of choroidal neovascularization. Retina, 2004, vol. 24:132-138.
Reich et al., Small interfering RNA (siRNA) targetingVEGFeffectively inhibits ocular neovascularization in a mouse model, 2003, Molecular Vision 9(31):210-216.
Shi et al., Inhibition of renal cell carcinoma angiogenesis and growth by antisense oligonucleotides targeting vascular endothelial growth factor, 2002, British Journal of Cancer 87:119-126.
Rubinson et al., A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference, Nat. Genetics, published online Feb. 18, 2003, doi: 10.1038
g1117, vol. 33(3):401-446 (ABSTRACT).
Shu et al., Sphingosine Kinase Mediates Vascular Endothelial Growth Factor-Induced Activation of Ras and Mitogen-Activated Protein Kinases, Nov. 2002, Mol. Cell Biol. 22(22):7758-7768.
Tuschl, 2002, The siRNA User Guide, rev. Oct. 11, 2002 http://www.mpibpc.gwdg.de/abteilungen/100/105/sima.html.
Van Brunt, Signals Magazine, Shoot the Messenger, http:www.signalsmag.com/signalsmag.../3DF5AEF6049C88256C1D0055BAA, Aug. 22, 2002.
Holash et al., VEGF-Trap: A VEGF blocker with potent antitumor effects, 2002, PNAS USA 99(17):11393-11398.
Kim et al., Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma, 2002, PNAS USA 99(17):11399-11404.
Novina et al., siRNA-directed inhibition of HIV-1 infection, 2002, Nat. Med. 8(7):681-686.
Xia et al., siRNA-mediated gene silencing in vitro and in vivo, 2002, Nat. Biotech. 20:1006-1010.
Elbashir et al., RNA interference is mediated by 21-and 22-nucleotide RNAs, 2001, Genes Dev. 15:188-200.
Elbashir et al., Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells, 2001, Nature 411:494-498.
Fire et al., Potent and specific genetic interference by double-stranded RNA inCaenorhabditis elegans, 1998, Nature 391:806-811.
Bennett et al., Humoral response after administration of E1-deleted adenoviruses: immune privilege of the subretinal space, 1996, Hum. Gene Ther. 7(14):1763-1769 (ABSTRACT).
Tischer et al., The human fene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing, Jun. 25, 1991, J. Biol. Chem. 266(18):11947-11954 (ABSTRACT).
Erickson, RNAi Revs Up, Oct. 2002, Start-Up, RNAi Revs Up (A#2002900168) pp. 1-12.
Houck et al., The Vascular Endothelial Growth Factor Family: Identification of a Fourth Molecular Species and Characterization of Alternative Splicing of RNA, 1991, Molecular Endoc. 5(12):1806-1814.
Brantl, Antisense-RNA regulation and RNA interference, 2002, Biochimica et Biophysics Acta 1575:15-25.

Affiliated with

Also associated with

Rating

Compositions and methods for siRNA inhibition of angiogenesis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions and methods for siRNA inhibition of angiogenesis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for siRNA inhibition of angiogenesis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3980993